

# AUSTRALIAN MADE ESTABLISHED 1958

# **Ilium Temvet Injection**

#### **Troy Laboratories Pty Ltd**

Chemwatch: **5398-98**Version No: **2.1.1.1** 

Safety Data Sheet according to WHS and ADG requirements

Chemwatch Hazard Alert Code: 0

Issue Date: **13/05/2020** Print Date: **14/05/2020** L.GHS.AUS.EN

#### SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

#### **Product Identifier**

Product name	Ilium Temvet Injection
Synonyms	APVMA number: 67612
Other means of identification	Not Available

## Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	For peri-operative and post-operative analgesia in cats. For post-operative analgesia and potentiation of the sedative effects of centrally acting
	agents in dogs. To be used as directed on product label. Therapeutic or pharmacologically-active agent. #28opan

#### Details of the supplier of the safety data sheet

Registered company name	Troy Laboratories Pty Ltd
Address	37 Glendenning Road Glendenning NSW 2761 Australia
Telephone	02 8808 3600
Fax	02 9677 9300
Website	www.Troylab.com.au
Email	admin@troylab.com.au

# Emergency telephone number

Association / Organisation	Troy Laboratories Pty Ltd
Emergency telephone numbers	02 8808 3600 (Office hours (8am – 4pm, Monday to Friday))
Other emergency telephone numbers	Not Available

# **SECTION 2 HAZARDS IDENTIFICATION**

## Classification of the substance or mixture

Poisons Schedule	S8
Classification [1]	Not Applicable

# Label elements

Hazard pictogram(s)	Not Applicable
SIGNAL WORD	NOT APPLICABLE

# Hazard statement(s)

Not Applicable

# Precautionary statement(s) Prevention

Not Applicable

#### Precautionary statement(s) Response

Not Applicable

#### Precautionary statement(s) Storage

Not Applicable

# Precautionary statement(s) Disposal

Not Applicable

#### **SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS**

#### Substances

Issue Date: **13/05/2020**Print Date: **14/05/2020** 

See section below for composition of Mixtures

#### Mixtures

CAS No	%[weight]	Name
59-50-7	<1	4-chloro-m-cresol
53152-21-9	<1	buprenorphine hydrochloride
Not Available	>60	Ingredients determined not to be hazardous

# **SECTION 4 FIRST AID MEASURES**

#### Description of first aid measures

Eye Contact	<ul> <li>If this product comes in contact with the eyes:</li> <li>Wash out immediately with fresh running water.</li> <li>Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>Seek medical attention without delay; if pain persists or recurs seek medical attention.</li> <li>Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
Skin Contact	If skin contact occurs:  Immediately remove all contaminated clothing, including footwear.  Flush skin and hair with running water (and soap if available).  Seek medical attention in event of irritation.
Inhalation	<ul> <li>If fumes, aerosols or combustion products are inhaled remove from contaminated area.</li> <li>Other measures are usually unnecessary.</li> </ul>
Ingestion	<ul> <li>For advice, contact a Poisons Information Centre or a doctor at once.</li> <li>Urgent hospital treatment is likely to be needed.</li> <li>If swallowed do NOT induce vomiting.</li> <li>If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> <li>Observe the patient carefully.</li> <li>Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.</li> <li>Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.</li> <li>Transport to hospital or doctor without delay.</li> </ul>

#### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

# **SECTION 5 FIREFIGHTING MEASURES**

## Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances. In such an event consider:

- ► foam.
- dry chemical powder.
- ▶ carbon dioxide.

### Special hazards arising from the substrate or mixture

Special nazarus arising from the substrate of mixture		
Fire Incompatibility	None known.	
Advice for firefighters		
Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves in the event of a fire.</li> <li>Prevent, by any means available, spillage from entering drains or water courses.</li> <li>Use fire fighting procedures suitable for surrounding area.</li> <li>DO NOT approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> <li>Equipment should be thoroughly decontaminated after use.</li> </ul>	
Fire/Explosion Hazard	<ul> <li>The material is not readily combustible under normal conditions.</li> <li>However, it will break down under fire conditions and the organic component may burn.</li> <li>Not considered to be a significant fire risk.</li> <li>Heat may cause expansion or decomposition with violent rupture of containers.</li> <li>Decomposes on heating and may produce toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> <li>Decomposes on heating and produces toxic fumes of: carbon dioxide (CO2) hydrogen chloride phosgene other pyrolysis products typical of burning organic material.</li> <li>May emit poisonous fumes.</li> <li>May emit corrosive fumes.</li> </ul>	
HAZCHEM	Not Applicable	

# **SECTION 6 ACCIDENTAL RELEASE MEASURES**

Chemwatch: 5398-98 Page 3 of 9 Version No: 2.1.1.1

# **Ilium Temvet Injection**

Issue Date: 13/05/2020 Print Date: 14/05/2020

# Personal precautions, protective equipment and emergency procedures

See section 8

#### **Environmental precautions**

See section 12

#### Methods and material for containment and cleaning up

Minor Spills	<ul> <li>Clean up all spills immediately.</li> <li>Avoid breathing vapours and contact with skin and eyes.</li> <li>Control personal contact with the substance, by using protective equipment.</li> <li>Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>Wipe up.</li> <li>Place in a suitable, labelled container for waste disposal.</li> </ul>
Major Spills	Moderate hazard.  Clear area of personnel and move upwind.  Alert Fire Brigade and tell them location and nature of hazard.  Wear breathing apparatus plus protective gloves.  Prevent, by any means available, spillage from entering drains or water course.  Stop leak if safe to do so.  Contain spill with sand, earth or vermiculite.  Collect recoverable product into labelled containers for recycling.  Neutralise/decontaminate residue (see Section 13 for specific agent).  Collect solid residues and seal in labelled drums for disposal.  Wash area and prevent runoff into drains.  After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.  If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

# **SECTION 7 HANDLING AND STORAGE**

Precautions for safe handling	
Safe handling	<ul> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>DO NOT allow material to contact humans, exposed food or food utensils.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> </ul>
Other information	NOTE: Special security requirements may be mandated under Federal/State Regulation(s).  Store in original containers.  Store in vault fitted with warning devices or detectors recommended by various Federal/State authorities.  Store in vault used only for the purpose of storage of drugs of addiction.  Vault must be locked at all times except when the materials stored therein are required.  Keep storage area free from debris, wastes and combustibles.  Keep dry.  Keep containers securely sealed.  Protect containers against physical damage.  Check regularly for spills and leaks.

#### Conditions for safe storage, including any incompatibilities

Suitable container	<ul> <li>Packaging as recommended by manufacturer.</li> <li>Check that containers are clearly labelled.</li> <li>Tamper-proof containers.</li> <li>Polyethylene or polypropylene containers.</li> <li>Metal drum with sealed plastic liner.</li> <li>Glass container is suitable for laboratory quantities</li> </ul>
Storage incompatibility	None known

# SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

# **Control parameters**

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Not Available

# **EMERGENCY LIMITS**

LINEKOLIOT LIMITO				
Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
4-chloro-m-cresol	Chloro-m-cresol, 4-	5.5 mg/m3	60 mg/m3	360 mg/m3

Chemwatch: **5398-98**Version No: **2.1.1.1** 

# Page 4 of 9 Ilium Temvet Injection

Issue Date: **13/05/2020**Print Date: **14/05/2020** 

Ingredient	Original IDLH	Revised IDLH
4-chloro-m-cresol	Not Available	Not Available
buprenorphine hydrochloride	Not Available	Not Available

#### OCCUPATIONAL EXPOSURE BANDING

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
4-chloro-m-cresol	E	≤ 0.01 mg/m³
buprenorphine hydrochloride	E	≤ 0.01 mg/m³
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.	

#### MATERIAL DATA

#### **Exposure controls**

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours.

Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg.

When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/containment technology.

Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies.

Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required.

Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, etc. evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

# Appropriate engineering controls

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of:

10; high efficiency particulate (HEPA) filters or cartridges

10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.

25-50; a full face-piece negative pressure respirator with HEPA filters  $\,$ 

50-100; tight-fitting, full face-piece HEPA PAPR

100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode.

#### Personal protection









Version No: 2.1.1.1

#### **Ilium Temvet Injection**

Issue Date: **13/05/2020**Print Date: **14/05/2020** 

When handling very small quantities of the material eve protection may not be required. For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs: ▶ Chemical goggles. ► Face shield. Full face shield may be required for supplementary but never for primary protection of eyes. F Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption Eye and face protection and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent] Skin protection See Hand protection below ▶ Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference Double gloving should be considered. PVC gloves. Hands/feet protection ► Change gloves frequently and when contaminated, punctured or torn. Wash hands immediately after removing gloves. ▶ Protective shoe covers. [AS/NZS 2210] ▶ Head covering. **Body protection** See Other protection below ▶ For quantities up to 500 grams a laboratory coat may be suitable. For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers. Other protection For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection. ► Eye wash unit. Ensure there is ready access to an emergency shower. ▶ For Emergencies: Vinyl suit

#### Recommended material(s)

#### GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

#### "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

Ilium Temvet Injection

Material	СРІ
BUTYL	A
NEOPRENE	A
VITON	А
NATURAL RUBBER	С
PVA	С

- \* CPI Chemwatch Performance Index
- A: Best Selection
- B: Satisfactory; may degrade after 4 hours continuous immersion
- C: Poor to Dangerous Choice for other than short term immersion

**NOTE**: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

#### Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1	-
up to 50	1000	-	A-AUS / Class 1
up to 50	5000	Airline *	-
up to 100	5000	-	A-2
up to 100	10000	-	A-3
100+			Airline**

- \* Continuous Flow \*\* Continuous-flow or positive pressure demand A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)
  - Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
  - The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
  - Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

#### **SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES**

Information on basic physical and chemical properties				
Appearance	Clear colourless liquid; mixes with water.			
Physical state	Liquid	Relative density (Water = 1)	1.017	
Odour	Not Available	Partition coefficient n-octanol / water	Not Available	
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable	
pH (as supplied)	4.5-5.5	Decomposition temperature	Not Available	

Chemwatch: **5398-98**Version No: **2.1.1.1** 

# Page 6 of 9 Ilium Temvet Injection

Issue Date: **13/05/2020**Print Date: **14/05/2020** 

Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

#### **SECTION 10 STABILITY AND REACTIVITY**

Reactivity	See section 7
Chemical stability	<ul> <li>Unstable in the presence of incompatible materials.</li> <li>Product is considered stable.</li> <li>Hazardous polymerisation will not occur.</li> </ul>
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

# **SECTION 11 TOXICOLOGICAL INFORMATION**

#### Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  Not normally a hazard due to non-volatile nature of product		
Ingestion	The material has <b>NOT</b> been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.		
Skin Contact	Skin contact is not thought to have harmful health effects (as classified under EC Directives); the material may still produce health damage following entry through wounds, lesions or abrasions.		
Еуе	Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).		
Chronic	Long-term exposure to the product is not thought to produce chronic effects adverse to health (as classified by EC Directives using animal models); nevertheless exposure by all routes should be minimised as a matter of course.		
	I		
	TOXICITY	IRRITATION	
Ilium Temvet Injection	Not Available	Not Available	

Ilium Temvet Injection	TOXICITY	IRRITATION
	Not Available	Not Available
	TOXICITY	IRRITATION
4-chloro-m-cresol	dermal (rat) LD50: >500 mg/kg <sup>[2]</sup>	Not Available
	Oral (rat) LD50: >=500 mg/kg <sup>[2]</sup>	
buprenorphine hydrochloride	TOXICITY	IRRITATION
	Oral (rat) LD50: >600 mg/kg <sup>[2]</sup>	Not Available
Legend:	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise	

Legend:

specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

#### 4-CHLORO-M-CRESOL

The following information refers to contact allergens as a group and may not be specific to this product.

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Side-reactions during manufacture of the parent compound may result in the production of trace amounts of polyhalogenated aromatic hydrocarbon(s). Halogenated phenols, and especially their alkali salts, can condense above 300 deg. C . to form polyphenoxyphenols or, in a

# Page 7 of 9 **Ilium Temvet Injection**

Issue Date: 13/05/2020 Print Date: 14/05/2020

very specific reaction, to form dibenzo-p-dioxins

Polyhalogenated aromatic hydrocarbons (PHAHs) comprise two major groups. The first group represented by the halogenated derivatives of dibenzodioxins (the chlorinated form is PCDD), dibenzofurans (PCDF) and biphenyls (PCB) exert their toxic effect (as hepatoxicants reproductive toxicants, immunotoxicants and procarcinogens) by interaction with a cytostolic protein known as the Ah receptor. In guinea pigs the Ah receptor is active in a mechanism which "pumps" PHAH into the cell whilst in humans the reverse appears to true. This, in part, may account for species differences often cited in the literature. This receptor exhibits an affinity for the planar members of this group and carries these to the cellular nucleus where they bind, reversibly, to specific genomes on DNA. This results in the regulation of the production of certain proteins which elicit the toxic response. The potency of the effect is dependent on the strength of the original interaction with the Ah receptor and is influenced by the degree of substitution by the halogen and the position of such substitutions on the parent compound.

The most potent molecule is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) while the coplanar PCBs (including mono-ortho coplanars) possess approximately 1% of this potency. Nevertheless, all are said to exhibit "dioxin-like" behaviour and in environmental and health assessments it has been the practice to assign each a TCDD-equivalence value.

The most subtle and important biological effects of the PHAHs are the effects on endocrine hormones and vitamin homeostasis. TCDD mimics the effect of thyroxin (a key metamorphosis signal during maturation) and may disrupt patterns of embryonic development at critical stages Individuals from exposed wildlife populations have been observed to have altered sexual development, sexual dysfunction as adults and immune system suppression. Immunotoxic effects of the PHAHs (including the brominated congener, PBB) have been the subject of several studies. No clear pattern emerges in human studies however with T-cell numbers and function (a blood marker for immunological response) increasing in some and decreasing in others.

Developmental toxicity (e.g. cleft palate, hydronephrosis) occurs in relatively few species; functional alterations following TCDD exposure leads to deficits in cognitive functions in monkeys and to adverse effects in the male reproductive system of rats.

Three incidences have occurred which have introduced abnormally high levels of dioxin or dioxin-like congeners to humans. The explosion at a trichlorophenol-manufacturing plant in Seveso, Italy distributed TCDD across a large area of the country-side, whilst rice-oil contaminated with heat-transfer PCBs (and dioxin-like contaminants) has been consumed by two groups, on separate occasions (one in Yusho, Japan and another in Yu-cheng, Taiwan). The only symptom which can unequivocally be related to all these exposures is the development of chloracne, a disfiguring skin condition, following each incident. Contaminated oil poisonings also produced eye-discharge, swelling of eyelids and visual disturbances. The Babies born up to 3 years after maternal exposure (so-called "Yusho-babies") were characteristically brown skinned, coloured gums and nails and (frequently) produced eye-discharges. Delays in intellectual development have been noted. It has been estimated that Yu-cheng patients consumed an average level of 0.06 mg/kg body weight/day total PCB and 0.0002 mg/kg/day of PCDF before the onset of symptoms after 3 months. When the oil was withdrawn after 6 months they had consumed 1 gm total PCB containing 3.8 mg PCDF. Taiwanese patients consumed 10 times as much contaminated oil as the Japanese patients (because of later withdrawal); however since PCB/PCDF concentration in the Japanese oil was 10 times that consumed in Taiwan, patients from both countries consumed about the same amount of PCBs/PCDFs. Preliminary data from the Yusho cohort suggests a six-fold excess of liver cancer mortality in males and a three-fold excess in women.

Recent findings from Seveso indicate that the biological effects of low level exposure (BELLEs), experienced by a cohort located at a great distance from the plant, may be hormetic, i.e. may be protective AGAINST the development of cancer. The PHAHs do not appear to be genotoxic - they do not alter the integrity of DNA. This contrasts with the effects of the many polycyclic aromatic hydrocarbons (PAHs) (or more properly, their reactive metabolites). TCDD induces carcinogenic effects in the laboratory in all species, strains and sexes tested. These effects are dose-related and occur in many organs. Exposures as low as 0.001 ug/kg body weight/day produce carcinoma. Several studies implicate PCBs in the development of liver cancer in workers as well as multi-site cancers in animals. The second major group of PHAH consists of the non-planar PCB congeners which possess two or more ortho-substituted halogens. These have been shown to produce neurotoxic effects which are thought to reduce the concentration of the brain neurotransmitter, dopamine, by inhibiting certain enzyme-mediated processes. The specific effect elicited by both classes of PHAH seems to depend on the as much on the developmental status of the organism at the time of the exposure as on the level of exposure over a lifetime

NOTE: Some jurisdictions require that health surveillance be conducted on workers occupationally exposed to polycyclic aromatic hydrocarbons. Such surveillance should emphasise

- ▶ demography, occupational and medical history
- health advice, including recognition of photosensitivity and skin changes
- physical examination if indicated
- records of personal exposure including photosensitivity

for 4-chloro-o-cresol (syn:4-chloro-2-methylphenol, PCOC)

Acute toxicity: PCOC is corrosive and toxic by inhalation but is only moderately toxic in acute mammalian tests by other routes. The substance is not a skin sensitizer. In an OECD screening test 422, PCOC did not cause reproductive effects in rats

Repeat dose toxicity: Tests for repeated dose toxicity suggest an NOAEL of 200 mg/kg and a LOAEL of 800/mg/kg (slight liver toxicity and decrease in haemoglobin concentration in the blood).

Repeat dose toxicity is not likely to present a major health problem. The margin of safety for workers based on a NOAEL of 200 mg/kg/day is 200/0.7 = 285. For the end-points irritation/corrosivity the concentration is below the level of concern

Genotoxicity: PCOC was positive in an older mouse micronucleus test, but negative in a recent valid test performed according to the current OECD guideline. It did not give rise to genotoxicity in valid Ames tests. On the basis of current knowledge, the substance can not be considered a mutagen.

#### BUPRENORPHINE **HYDROCHLORIDE**

Product: Oral (mouse) LD50: 260-261 mg/kg [Tasmanian Alkaloids] (Behavioural effects) Reproductive effects:- (Effects on Newborn- viability,

WARNING: Abuse can lead to habituation. Subject to Federal and State Regulations. Narcotic Substance, Schedule I (UN).

Acute Toxicity	×	Carcinogenicity	×
Skin Irritation/Corrosion	×	Reproductivity	×
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend:

X - Data either not available or does not fill the criteria for classification

Data available to make classification

#### **SECTION 12 ECOLOGICAL INFORMATION**

Chemwatch: 5398-98 Version No: 2.1.1.1

**Ilium Temvet Injection** 

Page 8 of 9 Issue Date: 13/05/2020 Print Date: 14/05/2020

buprenorphine hydrochloride	Not Available	Not Available	Not Available	Not Available	Not Available
4-chloro-m-cresol	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
	NOEC	672	Fish	0.15mg/L	2
	EC10	72	Algae or other aquatic plants	1.85mg/L	1
	EC50	72	Algae or other aquatic plants	4.2mg/L	1
	EC50	48	Crustacea	1.5mg/L	2
	LC50	96	Fish	0.917mg/L	4
	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
Ilium Temvet Injection	Not Available	Not Available	Not Available	Not Available	Not Available
	ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE

V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

#### DO NOT discharge into sewer or waterways.

#### Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
4-chloro-m-cresol	LOW (Half-life = 49 days)	LOW (Half-life = 0.67 days)

#### **Bioaccumulative potential**

Ingredient	Bioaccumulation
4-chloro-m-cresol	LOW (BCF = 13)

#### Mobility in soil

Ingredient	Mobility
4-chloro-m-cresol	LOW (KOC = 717.6)

#### **SECTION 13 DISPOSAL CONSIDERATIONS**

#### Waste treatment methods

Product / Packaging disposal

- ▶ Containers may still present a chemical hazard/ danger when empty.
- ▶ Return to supplier for reuse/ recycling if possible.

#### Otherwise:

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.

Valuable substance, hold all residues for recovery. Disposal of the material must be carried out in accordance with the requirements of the relevant Federal/State Act(s) or Code(s) regulating the disposal of Drugs of Addiction.

- Consult manufacturer/supplier for recycling options.
- Decontaminate empty containers with water; incinerate plastic bags.
- ▶ DO NOT reuse containers. Bury empty containers in an authorised landfill.
- ► DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- ▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- ► Recycle wherever possible.
- Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a licensed apparatus (after admixture with suitable combustible material).
- ▶ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

#### **SECTION 14 TRANSPORT INFORMATION**

#### Labels Required

4		
Marine Pollutant	NO	
HAZCHEM	Not Applicable	

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Page 9 of 9 **Ilium Temvet Injection**  Issue Date: 13/05/2020 Print Date: 14/05/2020

Not Applicable

#### **SECTION 15 REGULATORY INFORMATION**

#### Safety, health and environmental regulations / legislation specific for the substance or mixture

#### 4-CHLORO-M-CRESOL IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals Australia Inventory of Chemical Substances (AICS)

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 2

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 5

#### BUPRENORPHINE HYDROCHLORIDE IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Inventory of Chemical Substances (AICS)

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -

#### **National Inventory Status**

National Inventory	Status	
Australia - AICS	Yes	
Canada - DSL	No (buprenorphine hydrochloride)	
Canada - NDSL	No (4-chloro-m-cresol; buprenorphine hydrochloride)	
China - IECSC	No (buprenorphine hydrochloride)	
Europe - EINEC / ELINCS / NLP	Yes	
Japan - ENCS	No (buprenorphine hydrochloride)	
Korea - KECI	No (buprenorphine hydrochloride)	
New Zealand - NZIoC	Yes	
Philippines - PICCS	No (buprenorphine hydrochloride)	
USA - TSCA	No (buprenorphine hydrochloride)	
Taiwan - TCSI	Yes	
Mexico - INSQ	Yes	
Vietnam - NCI	No (buprenorphine hydrochloride)	
Russia - ARIPS	No (buprenorphine hydrochloride)	
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)	

# **SECTION 16 OTHER INFORMATION**

Revision Date	13/05/2020
Initial Date	13/05/2020

#### **SDS Version Summary**

Version	Issue Date	Sections Updated
2.1.1.1	13/05/2020	Classification, Ingredients

# Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### **Definitions and abbreviations**

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancel

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit。

IDLH: Immediately Dangerous to Life or Health Concentrations

OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level

LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value

LOD: Limit Of Detection

OTV: Odour Threshold Value

BCF: BioConcentration Factors

BEI: Biological Exposure Index

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.